Lv2
190 积分 2025-05-08 加入
Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study
10天前
已完结
Deriving Health Utility Values Using Mapping Methods Among the Chinese Population: A Systematic Review
24天前
已完结
Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer
2个月前
已完结
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective
2个月前
已关闭
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia
2个月前
已完结
Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China
2个月前
已关闭
PCN31 Systematic Review of Efficacy of Programmed Death (PD)-1 and PD-Ligand-1 Inhibitors in the Treatment of NON-SMALL CELL LUNG Cancer
4个月前
已关闭
1ISG-005 A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous non-small-cell lung cancer in second line in a healthcare setting
4个月前
已关闭
CP-123 A cost effectiveness analysis of nivolumab compared with pemetrexed for the treatment of non-small cell lung cancer in real practice
4个月前
已关闭
P3.07-001 Nivolumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis including PD-L1 Testing
4个月前
已完结
皖公网安备34019202002308
